Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib Journal Article


Authors: Quek, L.; David, M. D.; Kennedy, A.; Metzner, M.; Amatangelo, M.; Shih, A.; Stoilova, B.; Quivoron, C.; Heiblig, M.; Willekens, C.; Saada, V.; Alsafadi, S.; Vijayabaskar, M. S.; Peniket, A.; Bernard, O. A.; Agresta, S.; Yen, K.; MacBeth, K.; Stein, E.; Vassiliou, G. S.; Levine, R.; De Botton, S.; Thakurta, A.; Penard-Lacronique, V.; Vyas, P.
Article Title: Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
Abstract: Mutations in the gene encoding isocitrate dehydrogenase 2 (IDH2) occur in several types of cancer, including acute myeloid leukemia (AML). In model systems, mutant IDH2 causes hematopoietic differentiation arrest. Enasidenib, a selective small-molecule inhibitor of mutant IDH2, produces a clinical response in 40% of treated patients with relapsed/refractory AML by promoting leukemic cell differentiation. Here, we studied the clonal basis of response and acquired resistance to enasidenib treatment. Using sequential patient samples, we determined the clonal structure of hematopoietic cell populations at different stages of differentiation. Before therapy, IDH2-mutant clones showed variable differentiation arrest. Enasidenib treatment promoted hematopoietic differentiation from either terminal or ancestral mutant clones; less frequently, treatment promoted differentiation of nonmutant cells. Analysis of paired diagnosis/relapse samples did not identify second-site mutations in IDH2 at relapse. Instead, relapse arose by clonal evolution or selection of terminal or ancestral clones, thus highlighting multiple bypass pathways that could potentially be targeted to restore differentiation arrest. These results show how mapping of clonal structure in cell populations at different stages of differentiation can reveal the response and evolution of clones during treatment response and relapse. © 2018, The Author(s).
Journal Title: Nature Medicine
Volume: 24
Issue: 8
ISSN: 1078-8956
Publisher: Nature Publishing Group  
Date Published: 2018-08-01
Start Page: 1167
End Page: 1177
Language: English
DOI: 10.1038/s41591-018-0115-6
PROVIDER: scopus
PUBMED: 30013198
PMCID: PMC6925974
DOI/URL:
Notes: Article -- Export Date: 4 September 2018 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Eytan Moshe Stein
    342 Stein
  2. Alan H Shih
    59 Shih
  3. Ross Levine
    775 Levine